Literature DB >> 8780517

Two hierarchies of FGF-2 signaling in heparin: mitogenic stimulation and high-affinity binding/receptor transphosphorylation.

A Krufka1, S Guimond, A C Rapraeger.   

Abstract

FGF-2 activates multiple signaling pathways by a cell surface signaling complex assembled with FGF, its receptor tyrosine kinase, and heparan sulfate proteoglycan. Heparan sulfate binds to a site on the receptor and at least one site on the growth factor. Several models propose an important role for heparan sulfate not only in facilitating FGF-2 binding to its receptor tyrosine kinase but also in promoting signaling via formation of receptor dimers. Such dimers are capable of transphosphorylation of the cytoplasmic domain of the receptor, leading to the generation of phosphotyrosines that are important initiators of intracellular signaling pathways. To explore the participation of heparan sulfates in the formation of a signaling complex that activates these pathways, the binding and activity of FGF-2 on Swiss 3T3 fibroblasts and F32 lymphoid cells is examined with either native or modified forms of heparin. As shown previously, fibroblasts treated with chlorate, which inhibits the sulfation of heparan sulfate and its subsequent binding to FGF-2, display a dramatically reduced response to picomolar concentrations of FGF-2, but binding to receptors and a mitogenic response is restored by heparin. However, the restoration of high-affinity binding is seen only at an optimal concentration of heparin. Excess heparin competes for binding sites within the signaling complex such that high-affinity binding and receptor transphosphorylation are reduced. Despite this, mitogenic signaling is not diminished. A similar result is observed using heparin fragments that promote mitogenesis but not high-affinity binding. These results suggest that the high-affinity signaling complex that is necessary for stable receptor transphosphorylation differs from the signaling complex sufficient for triggering mitogenesis. We speculate that heparan sulfate in vivo participates in two hierarchies of receptor activation. In one, heparan sulfate participates in FGF-2 binding to its receptor tyrosine kinase and activation of mitogenic signaling, perhaps through monomeric receptors or the transient formation of receptor dimers. In the second hierarchy, heparan sulfate participates in the stabilization of a signaling complex that is likely to be comprised of receptor multimers that carry out effective receptor transphosphorylation. A further description of this mechanism may lead to an understanding of how heparan sulfate or its homologues can regulate specific signaling pathways within the cell.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780517     DOI: 10.1021/bi960125+

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

Review 1.  Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?

Authors:  R D Rosenberg; N W Shworak; J Liu; J J Schwartz; L Zhang
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

Review 2.  Generation of extracellular morphogen gradients: the case for diffusion.

Authors:  Kristina S Stapornwongkul; Jean-Paul Vincent
Journal:  Nat Rev Genet       Date:  2021-03-25       Impact factor: 53.242

3.  Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas.

Authors:  Christoph Mundhenke; Kristy Meyer; Sally Drew; Andreas Friedl
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 4.  Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.

Authors:  Derbis Campos; Madelyn Monaga
Journal:  Metab Brain Dis       Date:  2012-04-14       Impact factor: 3.584

5.  Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells.

Authors:  Chendong Pan; Matthew S Nelson; Morayma Reyes; Lisa Koodie; Joseph J Brazil; Elliot J Stephenson; Robert C Zhao; Charles Peters; Scott B Selleck; Sally E Stringer; Pankaj Gupta
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

6.  Structural and functional changes in heparan sulfate proteoglycan expression associated with the myofibroblastic phenotype.

Authors:  Gareth Thomas; Aled Clayton; Janet Thomas; Malcolm Davies; Robert Steadman
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

7.  Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization.

Authors:  Wan-Jong Kuo; Michelle A Digman; Arthur D Lander
Journal:  Mol Biol Cell       Date:  2010-09-22       Impact factor: 4.138

8.  Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis.

Authors:  Madhuchhanda Roy; Dario Marchetti
Journal:  J Cell Biochem       Date:  2009-02-01       Impact factor: 4.429

9.  Fractone-heparan sulphates mediate FGF-2 stimulation of cell proliferation in the adult subventricular zone.

Authors:  V Douet; A Kerever; E Arikawa-Hirasawa; F Mercier
Journal:  Cell Prolif       Date:  2013-04       Impact factor: 6.831

10.  Loop III region of platelet-derived growth factor (PDGF) B-chain mediates binding to PDGF receptors and heparin.

Authors:  D Schilling; J D Reid IV; A Hujer; D Morgan; E Demoll; P Bummer; R A Fenstermaker; D M Kaetzel
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.